These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 23390221)
1. Drug discovery algorithm for cutaneous leishmaniasis. Grogl M; Hickman M; Ellis W; Hudson T; Lazo JS; Sharlow ER; Johnson J; Berman J; Sciotti RJ Am J Trop Med Hyg; 2013 Feb; 88(2):216-21. PubMed ID: 23390221 [TBL] [Abstract][Full Text] [Related]
2. Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. Caridha D; Vesely B; van Bocxlaer K; Arana B; Mowbray CE; Rafati S; Uliana S; Reguera R; Kreishman-Deitrick M; Sciotti R; Buffet P; Croft SL Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():106-117. PubMed ID: 31320296 [TBL] [Abstract][Full Text] [Related]
3. In Vivo Bioluminescent Monitoring of Parasites in BALB/c Mouse Models of Cutaneous Leishmaniasis Drug Discovery. Caridha D; Leed S; Cawlfield A Methods Mol Biol; 2020; 2081():81-106. PubMed ID: 31721120 [TBL] [Abstract][Full Text] [Related]
4. A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis. Mears ER; Modabber F; Don R; Johnson GE PLoS Negl Trop Dis; 2015; 9(9):e0003889. PubMed ID: 26334763 [TBL] [Abstract][Full Text] [Related]
6. Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered Caridha D; Parriot S; Hudson TH; Lang T; Ngundam F; Leed S; Sena J; Harris M; O'Neil M; Sciotti R; Read L; Lecoeur H; Hickman M; Grogl M Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137819 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of NanoLuc, RedLuc and Luc2 as bioluminescent reporters in a cutaneous leishmaniasis model. Agostino VS; Trinconi CM; Galuppo MK; Price H; Uliana SRB Acta Trop; 2020 Jun; 206():105444. PubMed ID: 32173317 [TBL] [Abstract][Full Text] [Related]
8. [Drug discovery and development of vaccination strategies for the treatment and prevention of cutaneous leishmaniasis]. Schurigt U; Moll H Pharm Unserer Zeit; 2009; 38(6):532-7. PubMed ID: 19862713 [No Abstract] [Full Text] [Related]
9. Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis. Andrade-Neto VV; Cunha-Júnior EF; Canto-Cavalheiro MM; Atella GC; Fernandes TA; Costa PR; Torres-Santos EC Antimicrob Agents Chemother; 2016 Nov; 60(11):6844-6852. PubMed ID: 27600041 [TBL] [Abstract][Full Text] [Related]
11. Facilitating Drug Discovery in Human Disease Models Using Insects. Matsumoto Y Biol Pharm Bull; 2020; 43(2):216-220. PubMed ID: 32009109 [TBL] [Abstract][Full Text] [Related]
12. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Schmidt-Ott R; Klenner T; Overath P; Aebischer T Trans R Soc Trop Med Hyg; 1999; 93(1):85-90. PubMed ID: 10492799 [TBL] [Abstract][Full Text] [Related]
13. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. Rodriguez N; Bailey BN; Martin MB; Oldfield E; Urbina JA; Docampo R J Infect Dis; 2002 Jul; 186(1):138-40. PubMed ID: 12089677 [TBL] [Abstract][Full Text] [Related]
14. Oral Efficacy of Apigenin against Cutaneous Leishmaniasis: Involvement of Reactive Oxygen Species and Autophagy as a Mechanism of Action. Fonseca-Silva F; Inacio JD; Canto-Cavalheiro MM; Menna-Barreto RF; Almeida-Amaral EE PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004442. PubMed ID: 26862901 [TBL] [Abstract][Full Text] [Related]
15. [Cutaneous leishmaniasis in France: towards the end of injectable therapy?]. Buffet PA; Morizot G Bull Soc Pathol Exot; 2003 Jan; 96(5):383-8. PubMed ID: 15015844 [TBL] [Abstract][Full Text] [Related]
16. Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial. Iqbal J; Bukhari I; Jamshid M; Bashir S; Masoom Yasinzai M; Anwar M East Mediterr Health J; 2006 Sep; 12(5):685-9. PubMed ID: 17333810 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis. Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice. Santarem AA; Greggianin GF; Debastiani RG; Ribeiro JB; Polli DA; Sampaio RN Rev Soc Bras Med Trop; 2014 Jul; 47(4):517-20. PubMed ID: 25229296 [TBL] [Abstract][Full Text] [Related]
19. An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. Lage LM; Barichello JM; Lage DP; Mendonça DV; Carvalho AM; Rodrigues MR; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Coelho EA; Duarte MC Parasitol Res; 2016 Nov; 115(11):4083-4095. PubMed ID: 27365053 [TBL] [Abstract][Full Text] [Related]
20. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis. Eissa MM; Amer EI; El Sawy SM Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]